Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance

Stock Track11-12

Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The biopharmaceutical company has raised both its revenue and net product sales guidance, signaling growing confidence in its business trajectory.

The strong financial report has clearly energized investors, contributing to a remarkable run for Aurinia's stock. Over the past week, the company has seen a 13% share price return, and an even more impressive 32% gain over the past month. This recent surge is part of a broader trend, with the stock up nearly 70% year-to-date and delivering a total shareholder return of over 75% in the last twelve months.

While the recent performance has been stellar, opinions are divided on Aurinia's valuation. Some analysts suggest the stock may be overvalued, with a fair value estimate of $13.00 compared to the current price of $14.89. However, a discounted cash flow model indicates the stock might still be undervalued by 57.2%. As Aurinia continues to execute on its growth strategy, investors will be closely watching to see if the company can justify its current valuation and deliver sustained growth in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128418193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128418193","market":"sg","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The biopharmaceutical company has raised both its revenue and net product sales guidance, signaling growing confidence in its business trajectory.</p>\n\n<p>The strong financial report has clearly energized investors, contributing to a remarkable run for Aurinia's stock. Over the past week, the company has seen a 13% share price return, and an even more impressive 32% gain over the past month. This recent surge is part of a broader trend, with the stock up nearly 70% year-to-date and delivering a total shareholder return of over 75% in the last twelve months.</p>\n\n<p>While the recent performance has been stellar, opinions are divided on Aurinia's valuation. Some analysts suggest the stock may be overvalued, with a fair value estimate of $13.00 compared to the current price of $14.89. However, a discounted cash flow model indicates the stock might still be undervalued by 57.2%. As Aurinia continues to execute on its growth strategy, investors will be closely watching to see if the company can justify its current valuation and deliver sustained growth in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Soars 5.04% Following Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The biopharmaceutical company has raised both its revenue and net product sales guidance, signaling growing confidence in its business trajectory.</p>\n\n<p>The strong financial report has clearly energized investors, contributing to a remarkable run for Aurinia's stock. Over the past week, the company has seen a 13% share price return, and an even more impressive 32% gain over the past month. This recent surge is part of a broader trend, with the stock up nearly 70% year-to-date and delivering a total shareholder return of over 75% in the last twelve months.</p>\n\n<p>While the recent performance has been stellar, opinions are divided on Aurinia's valuation. Some analysts suggest the stock may be overvalued, with a fair value estimate of $13.00 compared to the current price of $14.89. However, a discounted cash flow model indicates the stock might still be undervalued by 57.2%. As Aurinia continues to execute on its growth strategy, investors will be closely watching to see if the company can justify its current valuation and deliver sustained growth in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1128418193","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128418193","pubTimestamp":1762887765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"个股赛道|Aurinia Pharmaceuticals继强劲的第三季度业绩并上调2025年指引后飙升5.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The biopharmaceutical company has raised both its revenue and net product sales guidance, signaling growing confidence in its business trajectory.\nThe strong financial report has clearly energized investors, contributing to a remarkable run for Aurinia's stock. Over the past week, the company has seen a 13% share price return, and an even more impressive 32% gain over the past month. This recent surge is part of a broader trend, with the stock up nearly 70% year-to-date and delivering a total shareholder return of over 75% in the last twelve months.\nWhile the recent performance has been stellar, opinions are divided on Aurinia's valuation. Some analysts suggest the stock may be overvalued, with a fair value estimate of $13.00 compared to the current price of $14.89. However, a discounted cash flow model indicates the stock might still be undervalued by 57.2%. As Aurinia continues to execute on its growth strategy, investors will be closely watching to see if the company can justify its current valuation and deliver sustained growth in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128418193","isCrawlerRequest":true}